Hristo Taskov

Prof. Dr. Hristo Taskov

orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in Journal of Molecular Biology
Verified
Journal Article
Closed access
MNMarina N. Nedelcheva
Marina N. Nedelcheva
ARAssen Roguev
Assen Roguev
LDLuben B. Dolapchiev
Luben B. Dolapchiev
ASAndrej Shevchenko
Andrej Shevchenko
HTHristo Taskov
Hristo Taskov
SSStoyno Stefanov Stoynov
Stoyno Stefanov Stoynov

1 March 2013 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
MNMaria Nikolova
Maria Nikolova
RMRoumiana Markova
Roumiana Markova
RDRumiana Drenska
Rumiana Drenska
MMMaria Muhtarova
Maria Muhtarova
YTYana Todorova
Yana Todorova
MAMassimo Amicosante
Massimo Amicosante

1 July 2000 in International Immunology
Verified
Journal Article
Open access
PDF file
VWVanessa E. Woodhead
Vanessa E. Woodhead
TSTimothy J. Stonehouse
Timothy J. Stonehouse
MBMichael H. Binks
Michael H. Binks
KSKatharina Speidel
Katharina Speidel
DFDavid A. Fox
David A. Fox
BCBenjamin M. Chain
Benjamin M. Chain
In this study we have re-examined the molecular mechanisms involved in activation of T cells by dendritic cells (DC). Human peripheral blood DC (PBDC) were derived by 2 h adhesion followed by 7 day culture in a combination of granulocyte macrophage colony stimulating factor and IL-4, and depletion of residual T and B cells. These PBDC were used to induce autologous T cell proliferation in a CD3-dependent response, and antibodies against CD11a/18 and CD86 were used as control inhibitors of accessory function. Antibodies against five of the cell surface molecules that we have recently identified on the surface of DC, CD13, CD87, CD98, CD147 and CD148, and an antibody which recognizes a molecule that has not as yet been identified, all inhibited the CD3-induced T cell proliferation. These findings were observed not only when antibodies were present throughout the culture, but also when they were prepulsed on to the surface of the DC, suggesting the inhibition was mediated via the antigen-presenting cells rather than the T cell. The same set of antibodies also inhibited an allospecific mixed lymphocyte reaction, confirming that the inhibitory effect was not dependent on the use of a CD3 antibody as the stimulating agent. All the antibodies of known specificity inhibited both CD4 and CD8 T cells equally. Unlike CD87, CD98 and CD147 antibodies, which inhibited activation of both CD45RA (naive) T cells and CD45RO (memory) T cells, CD13 and CD148 appeared to be involved in activation of naive cells only. The molecules identified in this study have not previously been demonstrated to play a role as accessory molecules on DC, the cells that are pivotal for immune induction. Therefore they may provide new potential targets for modulation of the immune response at the APC level.

19 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IAIvailo Alexiev
Ivailo Alexiev
DBDanail Beshkov
Danail Beshkov
ASAnupama Shankar
Anupama Shankar
DHDebra L. Hanson
Debra L. Hanson
Dimitrios ParaskevisDimitrios Paraskevis
Dimitrios Paraskevis
WSWilliam M. Switzer
William M. Switzer
Limited information is available to describe the molecular epidemiology of HIV-1 in Bulgaria. To better understand the genetic diversity and the epidemiologic dynamics of HIV-1 we analyzed 125 new polymerase (pol) sequences from Bulgarians diagnosed through 2009 and 77 pol sequences available from our previous study from persons infected prior to 2007. Epidemiologic and demographic information was obtained from each participant and phylogenetic analysis was used to infer HIV-1 evolutionary histories. 120 (59.5%) persons were infected with one of five different HIV-1 subtypes (A1, B, C, F1 and H) and 63 (31.2%) persons were infected with one of six different circulating recombinant forms (CRFs; 01_AE, 02_AG, 04_cpx, 05_DF, 14_BG, and 36_cpx). We also for the first time identified infection with two different clusters of unique A-like and F-like sub-subtype variants in 12 persons (5.9%) and seven unique recombinant forms (3.5%), including a novel J/C recombinant. While subtype B was the major genotype identified and was more prevalent in MSM and increased between 2000–2005, most non-B subtypes were present in persons ≥45 years old. CRF01_AE was the most common non-B subtype and was higher in women and IDUs relative to other risk groups combined. Our results show that HIV-1 infection in Bulgaria reflects the shifting distribution of genotypes coincident with the changing epidemiology of the HIV-1 epidemic among different risk groups. Our data support increased public health interventions targeting IDUs and MSM. Furthermore, the substantial and increasing HIV-1 genetic heterogeneity, combined with fluctuating infection dynamics, highlights the importance of sustained and expanded surveillance to prevent and control HIV-1 infection in Bulgaria.

1 April 1979 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MLMarie‐Luise Lohmann‐Matthes
Marie‐Luise Lohmann‐Matthes
WDWolfgang Domzig
Wolfgang Domzig
HTHristo Taskov
Hristo Taskov

1 January 2006 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MPMihaela Petrova
Mihaela Petrova
MMMaria Muhtarova
Maria Muhtarova
MNMaria Nikolova
Maria Nikolova
SMSvetoslav Magaev
Svetoslav Magaev
HTHristo Taskov
Hristo Taskov
ZKZahariy Krastev
Zahariy Krastev
AIM: To investigate reactivated Epstein-Barr virus (EBV) infection as a cause for chronic hepatitis. METHODS: Patients with occasionally established elevated serum aminotransferases were studied. HIV, HBV and HCV-infections were excluded as well as any other immunosuppressive factors, metabolic or toxic disorders. EBV viral capsid antigen (VCA) IgG and IgM, EA-R and EA-D IgG and Epstein-Barr nuclear antigen (EBNA) were measured using IFA kits. Immunophenotyping of whole blood was performed by multicolor flow cytometry. CD8+ T cell responses to EBV and PHA were determined according to the intracellular expression of IFN-γ. RESULTS: The mean alanine aminotransferase (ALT) and gamma glutamyl transpeptidase (GGTP) values exceeded twice the upper normal limit, AST/ALT ratio < 1. Serology tests showed reactivated EBV infection in all patients. Absolute number and percentages of T, B and NK cells were within the reference ranges. Fine subset analysis, in comparison to EBV+ healthy carriers, revealed a significant decrease of naive T cells (P < 0.001), accompanied by increased percentage of CD45RA- (P < 0.0001), and terminally differentiated CD28-CD27-CD8+ T cells (P < 0.01). Moderately elevated numbers of CD38 molecules on CD8+ T cells (P < 0.05) proposed a low viral burden. A significantly increased percentage of CD8+ T cells expressing IFN-γ in response to EBV and PHA stimulation was registered in patients, as compared to controls (P < 0.05). Liver biopsy specimens from 5 patients revealed nonspecific features of low-grade hepatitis. CONCLUSION: Chronic hepatitis might be a manifestation of chronic EBV infection in the lack of detectable immune deficiency; the expansion of CD28-CD27- and increase of functional EBV-specific CD8+ T cells being the only surrogate markers of viral activity.